medalphabetМедицинский алфавитMedical alphabet2078-56312949-2807ООО «Альфмед»10.33667/2078-5631-2024-19-16-20medalphabet-3894Research ArticleСтатьиКоррекция дефицита железа и железодефицитной анемии у женщин репродуктивного возраста: выбор перорального препарата в рамках концепции менеджмента крови пациентаCorrection of iron deficiency and iron deficiency anemia in women of reproductive age: choice of a drug within framework of concept of patient blood managementhttps://orcid.org/0000-0001-6714-6344ФедороваТ. А.FedorovaT. A.

Федорова Татьяна Анатольевна, д. м. н., проф., зам. директора Института анестезиологии, реаниматологии и трансфузиологии. Президент Национальной ассоциации специалистов менеджмента крови пациента

Москва

Fedorova Tatyana A., DM Sci (habil.), professor, deputy director of the Institute of Anesthesiology, Reanimatology and Transfusiology. President of the National Association of Patient Blood Management Specialists

Moscow

tfedorova1@mail.ruhttps://orcid.org/0000-0002-6926-8414СтрельниковаЕ. В.StrelnikovaE. V.

Стрельникова Елена Владимировна, к. м. н., врач высшей категории отделения экстракорпоральных методов лечения и детоксикации

Москва

Strelnikova Elena V., PhD Med, doctor of the highest category at Dept of Extracorporeal Methods of Treatment and Detoxification

Moscow

e_strelnikova@oparina4.ruhttps://orcid.org/0000-0001-5394-1910ХамидулинаК. Г.KhamidulinaK. G.

Хамидулина Ксения Геннадьевна, к. м. н., научный сотрудник отделения экстракорпоральных методов лечения и детоксикации

Москва

Khamidulina Ksenia G., PhD Med, researcher at Dept of Extracorporeal Treatment and Detoxification Methods

Moscow

ksenia_bykova@bk.ruФГБУ «Национальный медицинский исследовательский центр акушерства, гинекологии и перинатологии им. акад. В. И. Кулакова» Минздрава РФРоссияNational Medical Research Center for Obstetrics, Gynecology and Perinatology named after Academician V. I. KulakovRussian Federation202431102024019Современная гинекология (2)1620Copyright © Федорова Т.А., Стрельникова Е.В., Хамидулина К.Г., 20242024Федорова Т.А., Стрельникова Е.В., Хамидулина К.Г.Fedorova T.A., Strelnikova E.V., Khamidulina K.G.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-alphabet.com/jour/article/view/3894

В статье представлен обзор литературных и собственных данных по проблеме профилактики, диагностики и лечения дефицита железа и железодефицитной анемии у пациенток репродуктивного возраста с отягощенным соматическим статусом с развитием хронического воспалительного процесса. В концепции менеджмента крови пациента (МКП) диагностике и терапии анемии у пациенток, имеющих гинекологические заболевания, требующие в последующем оперативного лечения, уделяется первостепенное значение, так как анемия и дефицит железа рассматриваются как факторы риска худших исходов лечения пациенток. У женщин с гинекологической патологией нередко имеются заболевания, которые сопровождаются развитием реакции системного воспалительного ответа, что приводит к активации синтеза белка гепцидина и развитию так называемой анемии воспалительных заболеваний. Представлены данные, свидетельствующие об эффективности и безопасности препарата сукросомального железа (СидерАЛ® Форте) у пациенток акушерского и гинекологического стационара с повышением уровня С- реактивного белка в сочетании с дефицитом железа и железодефицитной анемией. Повышение феррокинетических показателей у пациенток, получающих сукросомальное железо, обусловлено уникальными физико-химическими и фармакокинетическими характеристиками сукросомы, что обеспечивает защиту сукросомального железа от воздействия желудочного сока, исключая контакт со слизистой желудочно-кишечного тракта и всасывание его через специальные М-клетки слизистой тонкого кишечника с последующим высвобождением железа в клетках печени. Препарат сукросомального железа является новым, удобным для приема, эффективным и хорошо переносимым по сравнению с традиционными пероральными препаратами железа.

The article presents a review of the literature and our own data on the problem of prevention, diagnosis and treatment of iron deficiency and iron deficiency anemia in patients of reproductive age with a burdened somatic status with the development of a chronic inflammatory process. In the concept of patient blood management (PBM), the diagnosis and treatment of anemia in patients with gynecological diseases requiring subsequent surgical treatment is given paramount importance, since anemia and iron deficiency are considered risk factors for worse treatment outcomes for patients. Women with gynecological pathology often have diseases that are accompanied by the development of a systemic inflammatory response, which leads to activation of hepcidin protein synthesis and the development of so-called anemia of inflammatory diseases. Data are presented indicating the effectiveness and safety of the sucrosomial iron drug (SiderAL® Forte) in obstetric and gynecological patients with increased levels of C-reactive protein in combination with iron deficiency and iron deficiency anemia. The increase in ferrokinetic parameters in patients receiving sucrosomial iron is due to the unique physicochemical and pharmacokinetic characteristics of sucrosome, which provides protection of sucrosomial iron from the effects of gastric juice, excluding contact with the mucous membrane of the gastrointestinal tract and its absorption through special M-cells of the small intestinal mucosa followed by the release of iron in liver cells. Sucrosomial iron is novel, convenient, effective, and well tolerated compared with traditional oral iron supplements.

менеджмент крови пациентаакушерство и гинекологиядефицит железа и железодефицитная анемиягепцидинвоспалительный процесссукросомальное железоэффективностьбезопасностьpatient blood managementobstetrics and gynecologyiron deficiency and iron deficiency anemiahepcidininflammatory processsucrosomial ironeffectivenesssafetyReferencesShander A, Hardy J-F, Ozawa S, Farmer SL, Hofmann A, Frank SM, et al. A global definition of Patient Blood Management. Anesth Analg. 2022; 135: 476–488. DOI: 10.1213/ANE.0000000000005873Shander A, Hardy J-F, Ozawa S, Farmer SL, Hofmann A, Frank SM, et al. A global definition of Patient Blood Management. Anesth Analg. 2022; 135: 476–488. DOI: 10.1213/ANE.0000000000005873Isbister J, Pearce BL, Delaforce AS, et al. Patients’ choice, consent, and ethics in patient blood management. Anesth Analg. 2022; 135: 489–500 WHO. Available at: https://apps.who.int/gb/ebwha/pdf_files/WHA63-REC1/WHA63_REC1-en.pdf. Accessed: February 2022Isbister J, Pearce BL, Delaforce AS, et al. Patients’ choice, consent, and ethics in patient blood management. Anesth Analg. 2022; 135: 489–500 WHO. Available at: https://apps.who.int/gb/ebwha/pdf_files/WHA63-REC1/WHA63_REC1-en.pdf. Accessed: February 2022Althoff FC, Neb H, Herrmann E, Trentino KM, Vernich L, Füllenbach C, et al. Multimodal Patient Blood Management Program based on a three-pillar strategy: a systematic review and meta-analysis. Ann Surg. 2019; 269: 794–804. DOI: 10.1097/SLA.0000000000003095Althoff FC, Neb H, Herrmann E, Trentino KM, Vernich L, Füllenbach C, et al. Multimodal Patient Blood Management Program based on a three-pillar strategy: a systematic review and meta-analysis. Ann Surg. 2019; 269: 794–804. DOI: 10.1097/SLA.0000000000003095Froessler B, Palm P, Weber I, Hodyl NA, Singh R, Murphy EM. The Important role for intravenous iron in perioperative patient blood management in major abdominal surgery: a randomized controlled trial. Ann Surg. 2016; 264 (1): 41–46. DOI: 10.1097/SLA.0000000000001646Froessler B, Palm P, Weber I, Hodyl NA, Singh R, Murphy EM. The Important role for intravenous iron in perioperative patient blood management in major abdominal surgery: a randomized controlled trial. Ann Surg. 2016; 264 (1): 41–46. DOI: 10.1097/SLA.0000000000001646Gupta PKMD, Sundaram AMMPH, MacTaggart JNMD, et al. Preoperative anemia is an independent predictor of postoperative mortality and adverse cardiac events in elderly patients undergoing elective vascular operations. Ann Surg 2013; 258: 1096–1102Gupta PKMD, Sundaram AMMPH, MacTaggart JNMD, et al. Preoperative anemia is an independent predictor of postoperative mortality and adverse cardiac events in elderly patients undergoing elective vascular operations. Ann Surg 2013; 258: 1096–1102Kloka JA, Friedrichson B, Jasny T, Old O, Piekarski F, Zacharowski K, Neef V. Anemia, red blood cell transfusion and administration of blood products in obstetrics: a nationwide analysis of more than 6 million cases from 2011–2020. Blood Transfus. 2024; 22: 37–45. DOI: 10.2450/BloodTransfus.528Kloka JA, Friedrichson B, Jasny T, Old O, Piekarski F, Zacharowski K, Neef V. Anemia, red blood cell transfusion and administration of blood products in obstetrics: a nationwide analysis of more than 6 million cases from 2011–2020. Blood Transfus. 2024; 22: 37–45. DOI: 10.2450/BloodTransfus.528Browning RM, Trentino K, Nathan EA, et al. Preoperative anaemia is common in patients undergoing major gynaecological surgery and is associated with a fivefold increased risk of transfusion. Aust N Z J Obstet Gynaecol 2012; 52: 455–459.Browning RM, Trentino K, Nathan EA, et al. Preoperative anaemia is common in patients undergoing major gynaecological surgery and is associated with a fivefold increased risk of transfusion. Aust N Z J Obstet Gynaecol 2012; 52: 455–459.Munro M. G. Practical aspects of the two FIGO systems for management of abnormal uterine bleeding in the reproductive years. Best Pract Res Clin Obstet Gynaecol. 2017; 40: 3–22. DOI: 10.1016/j.bpobgyn.2016.09.011Munro M. G. Practical aspects of the two FIGO systems for management of abnormal uterine bleeding in the reproductive years. Best Pract Res Clin Obstet Gynaecol. 2017; 40: 3–22. DOI: 10.1016/j.bpobgyn.2016.09.011Стуклов Н. И., Козинец Г. И., Леваков С. А., Огурцов П. П. Анемии при гинекологических и онкогинекологических заболеваниях. М.: МИА; 2013.Stuklov N. I., Kozinets G. I., Levakov S. A., Ogurtsov P. P. Anemia in gynecological and oncogynecological diseases. M.: MIA; 2013. (In Russ.).Стуклов Н. И. Железодефицитная анемия в практике гинеколога. Алгоритмы диагностики, профилактики и лечения. Акушерство и гинекология. 2016; 7: 99–104. http://dx.doi.org/10.18565/aig.2016.7.99–104Stuklov N. I. Iron deficiency anemia in the practice of a gynecologist. Algorithms for diagnosis, prevention and treatment. Obstetrics and gynecology. 2016; 7: 99–104 (In Russ.). http://dx.doi.org/10.18565/aig.2016.7.99–104Смирнов О. А. Железо-регуляторный гормон печени гепсидин и его место в системе врожденного иммунитета. Российский журнал гастроэнтерологии, гепатологии, колопроктологии.2010; 5: 10–4.Smirnov O. A. Iron is a liver regulatory hormone hepcidin and its place in the innate immune system. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2010; 5: 10–4. (In Russ.).Левина А. А., Казюкова Т. В., Цветаева Н. В. Гепсидин как регулятор гемостаза железа. Педиатрия. 2008; 87 (1): 67–74.Levina A. A., Kazyukova T. V., Tsvetaeva N. V. Hepcidin as a regulator of iron hemostasis. Pediatrics. 2008; 87 (1): 67–74. (In Russ.).Benotti PN, Wood GC, Kaberi-Otarod J, Still CD, Gerhard GS, Bistrian BR. New concepts in the diagnosis and management approach to iron deficiency in candidates for metabolic surgery: should we change our practice? Surg Obes Relat Dis. (2020) 16: 2074–81. DOI: 10.1016/j.soard.2020.08.018Benotti PN, Wood GC, Kaberi-Otarod J, Still CD, Gerhard GS, Bistrian BR. New concepts in the diagnosis and management approach to iron deficiency in candidates for metabolic surgery: should we change our practice? Surg Obes Relat Dis. (2020) 16: 2074–81. DOI: 10.1016/j.soard.2020.08.018Purdy JC, Shatzel JJ. The hematologic consequences of obesity. Eur J Haematol. (2021) 106: 306–19. DOI: 10.1111/ejh.13560Purdy JC, Shatzel JJ. The hematologic consequences of obesity. Eur J Haematol. (2021) 106: 306–19. DOI: 10.1111/ejh.13560Павлова В. Ю., Смольков М. А. Анемия хронических заболеваний. Лечащий Врач. 2021; 3 (24): 51–55.Pavlova V. Yu., Smolkov M. A. Anemia of chronic diseases. Attending doctor. 2021; 3 (24): 51–55. (In Russ.). DOI: 10.51793/OS.2021.24.3.010Цветаева Н. В., Левина А. А., Мамукова Ю. И. Основы регуляции обмена железа. Клиническая онкогематология. 2010; 3 (3): 278–283.Tsvetaeva N. V., Levina A. A., Mamukova Yu. I. Fundamentals of regulation of iron metabolism Clinical oncohematology. 2010; (3): 278–283. (In Russ.).Asperti M, Gryzik M, Brilli E, Castagna A, Corbella M, Gottardo R, Girelli D, Tarantino G, Arosio P, Poli M. Sucrosomial® Iron Supplementation in Mice: Effects on Blood Parameters, Hepcidin, and Inflammation. Nutrients. 2018 Sep 21; 10 (10): 1349. DOI: 10.3390/nu10101349Asperti M, Gryzik M, Brilli E, Castagna A, Corbella M, Gottardo R, Girelli D, Tarantino G, Arosio P, Poli M. Sucrosomial® Iron Supplementation in Mice: Effects on Blood Parameters, Hepcidin, and Inflammation. Nutrients. 2018 Sep 21; 10 (10): 1349. DOI: 10.3390/nu10101349Cappellini M. D., Comin-Colet J., de Francisco A., Dignass A., Doehner W., Lam C. S., Macdougall I. C., Rogler G., Camaschella C., Kadir R. et al. Iron deficiency across chronic inflammatory conditions: International expert opinion on definition, diagnosis, and management. Am. J. Hematol. 2017; 92: 1068–1078. DOI: 10.1002/ajh.248207Cappellini M. D., Comin-Colet J., de Francisco A., Dignass A., Doehner W., Lam C. S., Macdougall I. C., Rogler G., Camaschella C., Kadir R. et al. Iron deficiency across chronic inflammatory conditions: International expert opinion on definition, diagnosis, and management. Am. J. Hematol. 2017; 92: 1068–1078. DOI: 10.1002/ajh.248207Миронова О. Ю., Панферов А. С. Анемия хронических заболеваний: современное состояние проблемы и перспективы. Терапевтический архив. 2022; 94 (12): 1349–1354. DOI: 10.26442/00403660.2022.12.201984Mironova O. Yu., Panferov A. S. Anemia of chronic diseases: current state of the problem and prospects. Therapeutic archive. 2022; 94 (12): 1349–1354. (In Russ.). DOI: 10.26442/00403660.2022.12.201984Fletcher A, Forbes A, Svenson N. et al. Guideline for the laboratory diagnosis of iron deficiency in adults (excluding pregnancy) and children. Br. J. Haematol. 2021; 196 (3): 523–9. DOI: 10.1111/bjh.17900Fletcher A, Forbes A, Svenson N. et al. Guideline for the laboratory diagnosis of iron deficiency in adults (excluding pregnancy) and children. Br. J. Haematol. 2021; 196 (3): 523–9. DOI: 10.1111/bjh.17900De Franceschi L., Iolascon A., Taher A., Cappellini M. D. Clinical management of iron deficiency anemia in adults: Systemic review on advances in diagnosis and treatment. Eur. J. Intern. Med. 2017; 42: 16–23. DOI: 10.1016/j.ejim.2017.04.018De Franceschi L., Iolascon A., Taher A., Cappellini M. D. Clinical management of iron deficiency anemia in adults: Systemic review on advances in diagnosis and treatment. Eur. J. Intern. Med. 2017; 42: 16–23. DOI: 10.1016/j.ejim.2017.04.018Горохова С. Г., Ряженов В. В., Емченко И. В. Фармакоэкономическая оценка эффективности препаратов железа при коррекции анемии в ходе подготовки пациентов к обширным плановым оперативным вмешательствам. Клиническая фармакология и терапия. 2013; 22 (3): 47–52.Gorokhova S. G., Ryazhenov V. V., Emchenko I. V. Pharmacoeconomic assessment of the effectiveness of iron supplements in the correction of anemia during the preparation of patients for major planned surgical interventions. Clinical pharmacology and therapy. 2013; 22 (3): 47–52. (In Russ.).Стуклов Н. И., Семенова Е. Н. Лечение железодефицитной анемии. Что важнее, эффективность или переносимость? Существует ли оптимальное решение? Журнал международной медицины. 2013; 1 (2): 47–55.Stuklov N. I., Semenova E. N. Treatment of iron deficiency anemia. What is more important, effectiveness or tolerability? Is there an optimal solution? Journal of International Medicine. 2013; 1 (2): 47–55. (In Russ.).Gómez-Ramírez S., Brilli E., Tarantino G., Muñoz M. Sucrosomial® Iron: A New Generation Iron for Improving Oral Supplementation. Pharmaceuticals. 2018; 11: 97. DOI: 10.3390/ph11040097Gómez-Ramírez S., Brilli E., Tarantino G., Muñoz M. Sucrosomial® Iron: A New Generation Iron for Improving Oral Supplementation. Pharmaceuticals. 2018; 11: 97. DOI: 10.3390/ph11040097Вялов С. С. Железодефицитные состояния: клиника, диагностика и возможности лечения. Клиническая фармакология и терапия. 2015; 24 (4): 74–80.Vyalov S. S. Iron deficiency conditions: clinical picture, diagnosis and treatment options. Clinical pharmacology and therapy. 2015; 24 (4): 74–80. (In Russ.).Brilli E., Lipiński P., Barnadas R. et al. Sucrosomial Iron Absorption Involve M Cells Interaction. Blood. 2017; 130: 2217–2217. DOI: 10.1182/BLOOD.V130.SUPPL_1.2217.2217Brilli E., Lipiński P., Barnadas R. et al. Sucrosomial Iron Absorption Involve M Cells Interaction. Blood. 2017; 130: 2217–2217. DOI: 10.1182/BLOOD.V130.SUPPL_1.2217.2217Yu, P.P., Chang, Y.Z. and Yu, P. (2015) Iron Liposome: A More Effective Iron Supplement for Sports Anemia and Anemia of Inflammation. Journal of Pharmaceutical Care & Health Systems. 84: 1–3. https://doi.org/10.4172/2376–0419.S4–002Yu, P.P., Chang, Y.Z. and Yu, P. (2015) Iron Liposome: A More Effective Iron Supplement for Sports Anemia and Anemia of Inflammation. Journal of Pharmaceutical Care & Health Systems. 84: 1–3. https://doi.org/10.4172/2376–0419.S4–002Tarantino G., Brilli E., Zambito Y. et al. Sucrosomial® iron: A new highly bioavailable oral iron supplement. Blood. 2015; 126: 4561–4562. DOI:10.1182/Blood.V126.23.4561.4561Tarantino G., Brilli E., Zambito Y. et al. Sucrosomial® iron: A new highly bioavailable oral iron supplement. Blood. 2015; 126: 4561–4562. DOI:10.1182/Blood.V126.23.4561.4561Brilli E., Romano A., Fabiano A. et al. Sucrosomial® technology is able to promote ferric iron absorption: Pre-clinical and clinical evidences. Blood. 2016; 128: 3618. DOI: 10.1182/BLOOD.V128.22.3618.3618Brilli E., Romano A., Fabiano A. et al. Sucrosomial® technology is able to promote ferric iron absorption: Pre-clinical and clinical evidences. Blood. 2016; 128: 3618. DOI: 10.1182/BLOOD.V128.22.3618.3618Giordano G. Reduction of inflammatory markers with liposomal iron (Sideral®). Pre-clinical and clinical results. Exp. Rev. Hematol. 2016; 9 (Suppl. S 1): S 17. DOI: 10.1080/17474086.2016.1217153Giordano G. Reduction of inflammatory markers with liposomal iron (Sideral®). Pre-clinical and clinical results. Exp. Rev. Hematol. 2016; 9 (Suppl. S 1): S 17. DOI: 10.1080/17474086.2016.1217153Стуклов Н. И. Железодефицитные синдромы при заболеваниях желудочно-кишечного тракта: перспективы лечения. Клин. мед. 2016; 94 (6): 410–418. DOI: 10.18821/0023‑2149‑2016‑94‑6‑410‑418Stuklov N. I. Iron deficiency syndromes associated with diseases of the gastrointestinal tract: state-of-the-art and new prospects for treatment. Кlin. med. 2016; 94 (6): 410–418. (In Russ.). DOI: 10.18821/0023‑2149‑2016‑94‑6‑410‑418Gómez-Ramírez S, Brilli E, Tarantino G, Girelli D, Muñoz Manuel Sucrosomial® Iron: An Updated Review of Its Clinical Efficacy for the Treatment of Iron Deficiency Pharmaceuticals (Basel). 2023 Jun 6; 16 (6): 847. DOI: 10.3390/ph16060847Gómez-Ramírez S, Brilli E, Tarantino G, Girelli D, Muñoz Manuel Sucrosomial® Iron: An Updated Review of Its Clinical Efficacy for the Treatment of Iron Deficiency Pharmaceuticals (Basel). 2023 Jun 6; 16 (6): 847. DOI: 10.3390/ph16060847Mafodda A., Giuffrida D., Prestifilippo A., Azzarello D., Giannicola R., Mare M., Maisano R. Oral Sucrosomial® iron versus intravenous iron in anemic cancer patients without iron deficiency receiving darbepoetin alfa: A pilot study. Support. Care Cancer. 2017; 25: 2779–2786. DOI: 10.1007/s00520–017–3690-zMafodda A., Giuffrida D., Prestifilippo A., Azzarello D., Giannicola R., Mare M., Maisano R. Oral Sucrosomial® iron versus intravenous iron in anemic cancer patients without iron deficiency receiving darbepoetin alfa: A pilot study. Support. Care Cancer. 2017; 25: 2779–2786. DOI: 10.1007/s00520–017–3690-zBerardi S., Foltran L., Pascoli I., Pepe A., Salmeri M. G., Busato E. Efficacy of oral Sucrosomial® iron in puerperium anemia. Exp. Rev. Hematol. 2016;9 (Suppl. S 1): 40. DOI: 10.1080/17474086.2016.1217153Berardi S., Foltran L., Pascoli I., Pepe A., Salmeri M. G., Busato E. Efficacy of oral Sucrosomial® iron in puerperium anemia. Exp. Rev. Hematol. 2016;9 (Suppl. S 1): 40. DOI: 10.1080/17474086.2016.1217153Parisi, F., Brunetti, M., Fusè, F., Capriata, I., Mandò, C., Berti, C., et al. (2012) Relationship between Food Intake, Iron Supplementation, Haematochemical State and Outcomes in Pregnancy, in a Cohort of Pregnant Women in Italy. Woman – The Fascination of Modern Gynecology between Health and Woman Security: Upgrades and Necessities, Congress Palace, Montecatini Terme, Italy, 12–14 April 2012.Parisi, F., Brunetti, M., Fusè, F., Capriata, I., Mandò, C., Berti, C., et al. (2012) Relationship between Food Intake, Iron Supplementation, Haematochemical State and Outcomes in Pregnancy, in a Cohort of Pregnant Women in Italy. Woman – The Fascination of Modern Gynecology between Health and Woman Security: Upgrades and Necessities, Congress Palace, Montecatini Terme, Italy, 12–14 April 2012.Доброхотова Ю. Э., Романовская В. В., Нариманова М. Р. Новые подходы в лечении и профилактике анемии беременных. РМЖ. Мать и дитя. 2024; 7 (1): 26–34. DOI: 10.32364/2618‑8430‑2024‑7‑1‑4Dobrokhotova Yu.E., Romanovskaya V. V., Narimanova M. R. New approaches in the treatment and prevention of anemia in pregnant women. RMJ. Mother and child. 2024; 7 (1): 26–34. (In Russ.). DOI: 10.32364/2618‑8430‑2024‑7‑1‑4Parisi F., Berti C., Mando C., Martinelli A., Mazzali C., Cetin I. Effects of different regimens of iron prophylaxis on maternal iron status and pregnancy outcome: A randomized control trial. J. Matern. Fetal. Neonatal. Med. 2017; 30: 1787–1792. DOI: 10.1080/14767058.2016.1224841Parisi F., Berti C., Mando C., Martinelli A., Mazzali C., Cetin I. Effects of different regimens of iron prophylaxis on maternal iron status and pregnancy outcome: A randomized control trial. J. Matern. Fetal. Neonatal. Med. 2017; 30: 1787–1792. DOI: 10.1080/14767058.2016.1224841Antoine E., Mehedintu C., Mitran M., Diculescu D. Sucrosomial® iron effectiveness in recovering from mild and moderate iron-deficiency anemia in the postpartum period. BMC Pregnancy Childbirth. 2023; 23 (1): 360. DOI: 10.1186/s12884‑023‑05658‑7Antoine E., Mehedintu C., Mitran M., Diculescu D. Sucrosomial® iron effectiveness in recovering from mild and moderate iron-deficiency anemia in the postpartum period. BMC Pregnancy Childbirth. 2023; 23 (1): 360. DOI: 10.1186/s12884‑023‑05658‑7Федорова Т. А., Борзыкина О. М., Бакуридзе Э. М. Иванец Т. Ю., Cтрельникова Е. В., Цахилова С. Коррекция железодефицитной анемии у пациенток с гинекологическими заболеваниями с использованием липосомального железа. Гинекология. 2017; 19 (1): 68–73. URL: https://gynecology.orscience.ru/2079–5831/article/view/28629 ID: 28629Fedorova T. A., Borzykina O. M., Bakuridze E. M. Ivanets T. Yu., Strelnikova E. V., Tsakhilova S. Correction of iron deficiency anemia in patients with gynecological diseases using liposomal iron. Gynecology. 2017; 19 (1): 68–73. (In Russ.). URL: https://gynecology.orscience.ru/2079–5831/article/view/28629 ID: 28629Кононова И. Н., Доброхотова Ю. Э., Карева Е. Н., Шмакова Н. А., Грабан И. В., Огурцова Т. А. Оценка эффективности сукросомальной формы железа при лечении пациенток с железодефицитной анемией 1–2-й степени тяжести на фоне обильных менструальных кровотечений. РМЖ. Мать и дитя. 2023; 6 (4): 332–339. DOI: 10.32364/2618‑8430‑2023‑6‑4‑2Kononova I. N., Dobrokhotova Yu.E., Kareva E. N., Shmakova N. A., Graban I. V., Ogurtsova T. A. Evaluation of the effectiveness of the sucrosomal form of iron in the treatment of patients with iron deficiency anemia of the 1st‑2nd degree of severity against the background of heavy menstrual bleeding. RMJ. Mother and child. 2023; 6 (4): 332–339. (In Russ.). DOI: 10.32364/2618‑8430‑2023‑6‑4‑2Минушкин О. Н., Иванова О. И., Евсиков А. Е. Новые технологии лечения железодефицитных анемий. Эффективная фармакотерапия. 2022; 18 (42): 64–68. DOI 10.33978/2307‑3586‑2022‑18‑42‑64‑68Minushkin O. N., Ivanova O. I., Evsikov A. E. New technologies for the treatment of iron deficiency anemia. Effective pharmacotherapy. 2022; 18 (42): 64–68. (In Russ.). DOI 10.33978/2307‑3586‑2022‑18‑42‑64‑68Barni S., Gascon P., Petrelli F., Garcia-Erce J.A., Pedrazzoli P., Rosti G., Giordano G., Mafodda A., Munoz M. Position paper on management of iron deficiency in adult cancer patients. Expert Rev. Hematol. 2017; 10: 685–695. DOI: 10.1080/17474086.2017.1343140Barni S., Gascon P., Petrelli F., Garcia-Erce J.A., Pedrazzoli P., Rosti G., Giordano G., Mafodda A., Munoz M. Position paper on management of iron deficiency in adult cancer patients. Expert Rev. Hematol. 2017; 10: 685–695. DOI: 10.1080/17474086.2017.1343140Ciudin A., Simo-Servat O., Balibrea J. M., Vilallonga R., Hernandez C., Simo R., Mesa J. Response to oral Sucrosomial® iron supplementation in patients undergoing bariatric surgery. The BARI-FER study. Endocrinol. Diabetes Nutr. 2018; 65: 17–20. DOI: 10.1016/j.endinu.2017.10.007Ciudin A., Simo-Servat O., Balibrea J. M., Vilallonga R., Hernandez C., Simo R., Mesa J. Response to oral Sucrosomial® iron supplementation in patients undergoing bariatric surgery. The BARI-FER study. Endocrinol. Diabetes Nutr. 2018; 65: 17–20. DOI: 10.1016/j.endinu.2017.10.007Singh K, Sethi Chopra D, Singh D, Singh N. Nano-formulations in treatment of iron deficiency anaemia: An overview. Clin. Nutr. ESPEN. 2022 Dec; 52: 12–19. DOI: 10.1016/j.clnesp.2022.08.032. Epub 2022 Sep 6. PMID: 36513444Singh K, Sethi Chopra D, Singh D, Singh N. Nano-formulations in treatment of iron deficiency anaemia: An overview. Clin. Nutr. ESPEN. 2022 Dec; 52: 12–19. DOI: 10.1016/j.clnesp.2022.08.032. Epub 2022 Sep 6. PMID: 36513444Goobie S. M. Patient Blood Management Is a New Standard of Care to Optimize Blood Health. Anesthesia & Analgesia. 2022; 135 (3): 443–446. DOI: 10.1213/ANE.0000Goobie S. M. Patient Blood Management Is a New Standard of Care to Optimize Blood Health. Anesthesia & Analgesia. 2022; 135 (3): 443–446. DOI: 10.1213/ANE.0000

The authors declare that there are no conflicts of interest present.